GNLX Stock Forecast: Genelux Corp. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$2.28
+1.79% on the day

The median 12-month analyst price target for Genelux Corp. is $17. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 14 of 100 as at 18 Nov 2026 — in the weakest quartile.

Market cap
$109.6M
Ticker Nerd rank
14/ 100
Median analyst target
$17
Analysts covering
6
Revenue$0.0
Operating income−$9.6M
Net income−$9.5M
Free cash flow−$8.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+20.0%
1M
−6.9%
YTD
−47.7%
1Y
−54.4%
From 52W high
−59.2%
From 52W low
+25.3%
$1.82
$5.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Genelux Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
14/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
75
Volatility
67
Value
28
Growth
23
Revisions
23
Momentum
16
Issuance
15
Quality
9

Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GNLX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GNLX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00$35.00Jan 26Apr 26Jul 26Oct 26GNLXHigh $31Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$12
Low
$17
Median
$31
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Mar 2026BenchmarkMaintainsSpeculative Buy$23 → $20
21 Oct 2025Lake StreetInitiatesBuy—
21 July 2025LUCID CAPITAL MARKETSInitiatesBuy—
8 May 2025BenchmarkMaintainsSpeculative Buy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.MaintainsBuy—
29 Oct 2024GuggenheimInitiatesBuy—
27 Aug 2024Roth MKMInitiatesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
3 June 2024BenchmarkReiteratesSpeculative Buy—
31 May 2024BenchmarkMaintainsSpeculative Buy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024BenchmarkReiteratesSpeculative Buy—
2 Apr 2024HC Wainwright & Co.MaintainsBuy—
27 Nov 2023HC Wainwright & Co.InitiatesBuy—
24 Nov 2023BenchmarkMaintainsSpeculative Buy—
12 Sept 2023Maxim GroupInitiatesBuy—
9 June 2023BenchmarkMaintainsSpeculative Buy—
18 May 2023Brookline CapitalInitiatesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GNLX.

Market Radar

This page is one stock. Monday covers all of them.

GNLX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GNLX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Genelux Corp. returned −54.4% against +9.2% for the S&P 500, dividends included.

GNLX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26GNLXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GNLX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
13698.3×

Cheaper than 1% of US stocks

Price / book
11.3×

Cheaper than 7% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−273.2%

Higher than 5% of US stocks

Return on assets
−105.9%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Genelux Corp. has a market value of $109.6M and an enterprise value of $99.6M.

  • Revenue in the twelve months to 30 June 2026: $8K.

  • Net income over the same four quarters: −$35.6M, a −444950.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$28.7M.

  • Shares outstanding: 45.1M.

  • Genelux Corp. employs 25 people — $320.0 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Nov 2026

Data provided by Twelve Data

Peers

GNLX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GNLXGenelux Corp.$109.6M14
NERVMinerva Neurosciences, Inc.$108.6M28
CNTNCanton Strategic Holdings, Inc.$109.0M7
CMPXCompass Therapeutics, Inc.$110.0M29
FHTXFoghorn Therapeutics, Inc.$104.9M56
CBUSCibus, Inc.$104.4M27
UNCYUnicycive Therapeutics, Inc.$104.2M36

Take a look at GNLX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Genelux Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GNLX

What is the GNLX stock price forecast for 2026-2027?

The median 12-month analyst price target for Genelux Corp. is $17, with estimates ranging from $12 to $31. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GNLX stock a buy right now?

Of the 6 analysts covering Genelux Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genelux Corp. 14 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GNLX?

As at 18 Nov 2026, Genelux Corp. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).

Will GNLX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts is $17, and Ticker Nerd's factor model ranks Genelux Corp. 14 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GNLX stock forecast for 2030?

No analyst covering Genelux Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNLX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $31 over the next 12 months.

How has GNLX stock performed over the past year?

Genelux Corp. returned -54.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Genelux Corp. do?

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response.

Company

About Genelux Corp.

Genelux Corporation is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. Its lead program, Olvi-Vec, is a modified vaccinia virus-based candidate designed to selectively target cancer cells while stimulating an anti-tumor immune response. The company also advances CHOICE, a discovery and development platform, alongside a broader pipeline of engineered virus-based product candidates. Genelux serves the oncology market through drug research, development, and clinical trial services centered on immuno-oncology applications. Headquartered in Westlake Village, California, Genelux Corporation concentrates on current therapeutic programs and specialty biotechnology solutions aimed at addressing unmet needs in cancer treatment.

CEO Mr. Thomas D. Zindrick J.D. · 25 employees · United States · https://www.genelux.com